US Corporate Board Director Changes SEC Filings — September 10, 2026

USA Board Room Changes

By Gunpowder Editorial ·

37 high priority 37 total filings analysed

Executive Summary

This batch of 37 filings reveals a high volume of board room changes across sectors, including a notable cluster of significant CFO and board transitions.

A key trend is the prevalence of restructurings and leadership overhauls at smaller, struggling companies, such as the complete C-suite departure at Two Harbors Investment Corp (TWOD) and a major business pivot at CVD Equipment Corporation (CVV). Conversely, several larger firms are making strategic appointments, such as TransMedics (TMDX) hiring a CFO from GE HealthCare and Insulet (PODD) seeing two long-tenured directors depart. Sentiment across the portfolio is predominantly neutral, but two events stand out as highly material: the Five Senior Officer departures at Two Harbors (negative) and the major restructuring at CVD Equipment (negative). Forward-looking data from Candel Therapeutics and TransMedics provides clear catalysts, such as a planned BLA submission and a reiterated growth guidance, respectively. A critical warning signal emerges from NIKE, where 32% of shareholders voted against executive compensation, indicating significant governance concerns. The high concentration of CFO changes (Fortrea, Village Farms, New Fortress Energy, TransMedics, CVD Equipment, Whitehawk, SCYNEXIS, Versus Systems, Golden Minerals, AptarGroup) suggests a broader trend of financial leadership rotation.

Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →

Filing types in this digest: 8-K

Tracking the trend? Catch up on the prior US Corporate Board Director Changes SEC Filings digest from September 09, 2026.

Investment Signals (9)

  • Hired new CFO Fernando Araujo from GE HealthCare's $16B division, reiterated FY2026 revenue guidance of $737M-$757M (22-25% YoY growth), and appointed former CFO to lead Latin American expansion. This dual move strengthens financial leadership and opens a new growth frontier.

  • Appointed former Ipsen/Alexion regulatory expert Martine Zimmermann to the Board ahead of a planned BLA submission for aglatimagene besadenovec in Q4 2026. The asset has multiple FDA designations; this signals strong preparation for a key catalyst.

  • Dexcom (BULLISH)

    Appointed former Stryker CFO Glenn Boehnlein to its Board, bringing over 20 years of MedTech financial leadership. This could signal a focus on operational efficiency and long-range planning amid CGM market competition.

  • Appointed oncology veteran Dr. Vijay Iyengar to the Board, who helped grow Incyte's revenue from ~$1B to over $4B. This strengthens commercial expertise as the company advances its ADC pipeline.

  • Appointed former CEO David Bailey as CCO to drive revenue growth. Bailey led the company through its landmark FDA ICL approval in 2005 and commercial launches across Asia, a critical region for the EVO ICL.

  • Reinstated CFO Jason Knoblauch after settling a lawsuit with his former employer. While the removal of legal overhang is a positive, the event itself reveals a significant governance and legal risk that has now been resolved. [NEUTRAL turning BULLISH]

  • NIKE (BEARISH)

    Advisory vote on executive compensation received 32% 'against' votes, a high level of dissent. While all proposals passed, this is a clear red flag on shareholder sentiment regarding pay-for-performance alignment.

  • Announced a well-structured CEO succession plan. Michael Colwell becomes President/COO in October and CEO in January, while current CEO Jeffrey Powell transitions to Executive Chairman for a year. This ensures leadership continuity and knowledge transfer.

  • Appointed Brantley Standridge as President, with a significant compensation package including a $1M salary and $4.65M LTI target. This signals a strategic bet on an internal candidate to drive the bank's future.

Risk Flags (9)

  • Five senior officers (CFO, CIO, CLO, CRO, CAO) departed immediately on Sept 4, 2026, classified as 'Qualifying Terminations' during a 'Change of Control Period.' CEO is also leaving Oct 2. This represents a catastrophic loss of institutional knowledge and extreme execution risk.

  • Company is discontinuing new system orders, cutting workforce by ~50%, taking a $0.8M-$1.0M charge, and its CEO has left. While it has $23.5M cash and no debt, this is a fundamental business pivot from a position of weakness.

  • Independent Director Ross Miller submitted two conflicting resignation letters citing a 'breakdown in communication' and differences over company direction. The Board's failure to act or clarify its position creates severe governance uncertainty.

  • 32% of votes were cast against executive compensation (349.5M shares). This is a very high level of opposition and often precedes shareholder activism or significant board/compensation committee changes.

  • The Chairperson, CEO, President, CFO, and Secretary all resigned simultaneously. New leadership has been appointed but with a track record that is opaque to US investors, creating significant operational and governance risk.

  • The departure of Chairman Tim Scannell (12 yrs) and director Michael Minogue creates a vacuum in board leadership, especially as Minogue leaves to run for political office, which could be a distraction.

  • Filed an 8-K disclosing an officer change and bylaw amendments without specifying the position, reason, or detail on the amendments. This lack of transparency is a major red flag for governance and shareholder rights.

  • Paying Executive Harold Carpenter $1.5M to maintain non-compete and non-solicitation covenants through March 2027. This suggests a high reliance on this individual and a risk if the covenants are breached.

  • Appointed the Chief Accounting Officer as interim CFO while the Board searches for a permanent one. With the CAO having only joined in June 2025, this signals potential instability or a lack of senior financial leadership.

Opportunities (6)

  • TransMedics (TMDX) / Strong Growth & New Leadership (OPPORTUNITY)

    The reiteration of 22-25% revenue growth for FY2026, combined with a new CFO from a GE HealthCare mega-segment and a dedicated leader for Latin American expansion, presents a strong growth narrative.

  • Candel Therapeutics (CADL) / BLA Catalyst (OPPORTUNITY)

    The appointment of a regulatory expert to the Board directly aligns with the planned Q4 2026 BLA submission for aglatimagene besadenovec. Success would transform this clinical-stage company into a commercial entity.

  • STAAR Surgical (STAA) / Commercial Firepower (OPPORTUNITY)

    Appointing a former CEO with deep international experience, especially in Asia (China, South Korea), as CCO is a move to capitalize on the shift from laser to ICL. Bailey's track record of securing FDA approval and launching in Asia is directly applicable.

  • Fortrea Holdings (FTRE) / Legal Overhang Removed (OPPORTUNITY)

    The settlement with the former employer and reinstatement of the original CFO removes a major legal and operational overhang that has been a cloud over the stock.

  • Dexcom (DXCM) / MedTech Financial Expertise (OPPORTUNITY)

    Glenn Boehnlein's appointment adds significant financial discipline from a large-cap MedTech leader (Stryker). This could signal a focus on profitability and capital efficiency, a trend investors appreciate.

  • Portfolio Play: CFO Rotation Cycle

    The sheer volume of CFO changes (Fortrea, Village Farms, New Fortress, TransMedics, CVD, SCYNEXIS, Versus, Golden Minerals, AptarGroup) creates opportunities to analyze the

Sector Themes (5)

  • Small-Cap Restructuring Wave

    A cluster of small and micro-cap companies (CVD Equipment, Two Harbors, VitaSpring, Summit Networks) are undergoing deep restructuring, leadership overhauls, or facing governance crises. This highlights a period of acute stress in this market segment.

  • Strategic Medical Device Appointments

    Both STAAR Surgical and Dexcom are adding seasoned medical device executives to key roles (CCO and Board, respectively), signaling a focus on commercial execution and strategic financial planning in a competitive MedTech landscape.

  • Specialty Pharma/Biotech Board Building for Catalyst

    Candel Therapeutics and Whitehawk Therapeutics are both adding board members with deep regulatory and commercial experience as they approach major clinical or regulatory milestones (BLA submission, ADC pipeline progress). This pattern suggests a focus on derisking late-stage development and preparing for commercialization.

  • Financial Services Talent Rotation

    Huntington Bancshares and Pinnacle Financial Partners are making strategic investments in key executive talent (President appointment, non-compete payments). This suggests a competitive market for leadership in the regional banking space.

  • Governance and Compensation Pushback

    NIKE's 32% 'against' vote on say-on-pay is a high-profile example of potential shareholder discontent. This could be a leading indicator of broader investor scrutiny on compensation practices across large-cap consumer and retail companies.

Watch List (8)

  • Monitor for further departures, the selection of a new CEO and CFO, and any strategic shift following the 'Change of Control Period' loss of five senior officers. The situation is fluid and high risk.

  • Watch the restructuring progress, the success of the pivot to a parts/service business, and any updates on monetizing its facility. The Q3 earnings call for restructuring charge details is a key event.

  • Candel Therapeutics (CADL)
    👁

    Watch for any updates on the BLA submission timeline or additional regulatory interactions for aglatimagene besadenovec, which is a major catalyst expected in Q4 2026.

  • TransMedics (TMDX)
    👁

    Monitor future guidance updates on Q3 2026 earnings call, especially any contribution from the PAD Aviation investment, and progress on the Latin American expansion under Gerardo Hernandez.

  • Watch for any Board action regarding the director's conflicting resignation letters. A lack of clear communication could lead to further governance issues.

  • NIKE (NKE)
    👁

    Monitor for any shareholder proposals or activist activity following the high say-on-pay dissent. The annual meeting results warrant attention for potential future governance battles.

  • Fortrea Holdings (FTRE)
    👁

    Watch for the first earnings report under the reinstated CFO Jason Knoblauch (likely Q3 2026 in late Oct/early Nov). The settlement removes a major distraction, allowing management to focus on operations.

  • Monitor the transition period starting Oct 1 as Michael Colwell becomes President/COO, leading up to his CEO appointment on Jan 2, 2027. Any early communication of strategic priorities will be key.

Filing Analyses (37)
MEXCO ENERGY CORP 8-K positive materiality 3/10

10-09-2026

Mexco Energy Corporation held its 2026 Annual Meeting on September 8, 2026, where stockholders elected five directors, ratified Weaver & Tidwell as auditor, approved the amended 2019 employee incentive stock plan, and approved a non-binding advisory vote on executive compensation. All proposals received strong support, with the incentive plan passing by 1,538,624 votes for versus 67,868 against. The company also disclosed amendments to the incentive plan and related award agreements.

  • · The company had 2,046,000 shares of common stock outstanding and entitled to vote as of July 20, 2026.
  • · 1,649,149 shares (constituting a quorum) were represented at the meeting.
  • · All five director nominees received over 1.6 million votes for, with less than 16,000 votes withheld each.
  • · Ratification of auditor was overwhelmingly approved: 1,634,808 for, 14,334 against, and 7 abstained.
  • · The compensated advisory vote on executive compensation passed: 1,593,300 for, 6,173 against, 16,735 abstained.
  • · The incentive stock plan was approved with 1,538,624 votes for, 67,868 against, and 9,716 abstained.
STAAR SURGICAL CO 8-K positive materiality 6/10

10-09-2026

STAAR Surgical appointed former CEO David Bailey as Chief Commercial Officer, effective September 8, 2026. Bailey, who led the company from 2001 to 2011 and raised over $60 million, returns to drive revenue growth as EVO ICL gains share from a declining laser refractive market. The appointment underscores STAAR's strategic focus on expanding its phakic IOL leadership amid stagnating laser procedures globally.

  • · Bailey served as President and CEO from 2001 to 2008 and as President of International Operations from 2008 to 2011.
  • · He secured landmark FDA approval of the ICL in 2005.
  • · He directed commercial launches in China, South Korea, and across Asia.
  • · He acquired STAAR's Canon joint venture in Japan, securing exclusive control of patents and proprietary technology worldwide.
  • · ICL revenues have grown more than tenfold since 2011 (from ~$32M).
  • · Bailey will attend the 44th Congress of the ESCRS in London from September 11–15, 2026.
  • · STAAR has sold more than 4 million ICLs in over 85 countries.
  • · The company operates facilities in California and Switzerland.
Mobileye Global Inc. 8-K neutral materiality 1/10

10-09-2026

Mobileye Global Inc. announced on September 3, 2026, that its Board designated Chief Operating Officer Yaacov "Kobi" Ohayon as the principal operating officer and an executive officer under Section 16 of the Exchange Act. The change formalizes Mr. Ohayon's existing responsibilities, which have expanded since 2020, and does not modify his duties, employment status, or compensation. The filing reflects an internal governance adjustment with no financial impact on operations or performance.

  • · Yaacov "Kobi" Ohayon, age 51, has been with Mobileye since 2017 and served as COO since 2020.
  • · Ohayon entered into the company's standard form of officers' indemnification agreement.
  • · No family relationships exist between Ohayon and any director or executive officer, and he is not party to any disclosable related-party transaction.
Mobileye Global Inc. 8-K neutral materiality 3/10

10-09-2026

Mobileye Global Inc. announced that EVP of Business Development & Strategy Nimrod Nehushtan will transition to a part-time corporate strategy role effective September 3, 2026. His compensation arrangements remain unchanged. VP of Business Development Nimrod Brickman will continue leading business development activities.

  • · No financial figures or performance metrics were disclosed in the filing.
  • · The transition is effective immediately as of September 3, 2026.
  • · Mr. Nehushtan's existing compensation arrangements have not been modified.
Fortrea Holdings Inc. 8-K neutral materiality 5/10

10-09-2026

Fortrea Holdings reinstated Jason Knoblauch as CFO and principal financial officer on September 9, 2026, following a settlement with his former employer that resolved a lawsuit alleging breach of restrictive covenants and retention of confidential information. David Smith, who served as Interim CFO during Knoblauch's leave, stepped down from that role but remains on the Board. The reinstatement follows a temporary restraining order issued by the Delaware Court of Chancery on July 25, 2026, which had prevented Knoblauch from serving as CFO.

  • · The settlement agreement and mutual release resolved the lawsuit filed by Knoblauch's prior employer.
  • · Knoblauch's compensation package remains unchanged from that disclosed in the June 26, 2026 Form 8-K.
  • · The temporary restraining order was issued on July 25, 2026, and was lifted as part of the settlement.
Pinnacle Financial Partners, Inc. 8-K neutral materiality 4/10

10-09-2026

Pinnacle Financial Partners amended a non-compete and cooperation agreement with Harold R. Carpenter, extending the term through March 31, 2027. In exchange, the company will accelerate a $1,000,000 payment to October 1, 2026, and pay an additional $500,000 in March 2027. These payments are subject to forfeiture or clawback if Mr. Carpenter breaches the non-compete covenant.

  • · The original letter agreement was dated January 14, 2026.
  • · The non-compete and non-solicitation covenants now run through March 31, 2027.
  • · Mr. Carpenter must also provide as-needed conversion-related assistance directed by Robert A. McCabe.
  • · The previously scheduled payment date for the $1,000,000 second installment was on or after January 1, 2027.
Village Farms International, Inc. 8-K neutral materiality 5/10

10-09-2026

Village Farms International appointed Hamid Shekarchi as Interim CFO, effective immediately, succeeding Steve Ruffini who remains on the leadership team overseeing M&A. Shekarchi, previously CFO of the company's Canadian cannabis business, brings 18 years of financial leadership experience. The appointment follows a thorough search process as part of the previously announced CFO succession plan from April 3, 2026.

  • · Shekarchi previously co-led BDO's Western Canada Cannabis practice and held senior roles at BDO Canada and PwC.
  • · He is a Chartered Professional Accountant (CPA, CA) and Chartered Business Valuator (CBV).
  • · He is a graduate of Simon Fraser University and a past recipient of Business in Vancouver's Forty Under 40 Award.
  • · The company operates over 7 million square feet of advanced greenhouse and indoor cultivation assets.
  • · Village Farms operates the world's largest EU-GMP certified cannabis facility in Delta, British Columbia.
INSULET CORP 8-K neutral materiality 4/10

10-09-2026

Insulet Corporation announced the departures of two directors from its Board. Timothy J. Scannell stepped down effective September 3, 2026, for health reasons after 12 years of service, including 7 years as Chairman. Michael R. Minogue also notified his resignation effective September 15, 2026, to focus on his candidacy for Governor of Massachusetts. Both departures were not due to any disagreement with the company's operations, policies, or practices.

CARLISLE COMPANIES INC 8-K neutral materiality 3/10

10-09-2026

Jesse G. Singh resigned as a director of Carlisle Companies Incorporated effective September 10, 2026, due to a change in his employment, in accordance with the company's corporate governance guidelines. The Board reduced its size to six directors. Mr. Singh's resignation was not due to any disagreement with the company, and he served for over eight years.

  • · Mr. Singh resigned at the conclusion of the Board meeting on September 10, 2026.
  • · The resignation was due to a change in his employment, not a disagreement with the company.
  • · The Board fixed the number of directors at six following the resignation.
TWO HARBORS INVESTMENT CORP. 8-K negative materiality 8/10

10-09-2026

Two Harbors Investment Corp. (TWOD) announced the immediate departure of five senior officers on September 4, 2026, including the CFO, CIO, CLO, CRO, and CAO, all treated as Qualifying Terminations during a Change of Control Period under the company's Severance Benefits Plan. CEO William Greenberg will remain until October 2, 2026, when his employment is expected to terminate. Madhur Agarwal, CFO of parent company CrossCountry Mortgage, was appointed as TWO's CFO effective immediately, serving concurrently without additional compensation from TWO.

  • · The departures are classified as 'Qualifying Termination' during a 'Change of Control Period' under the Two Harbors Investment Corp. Severance Benefits Plan, as amended and restated effective December 16, 2025.
  • · Each departing officer has entered or is expected to enter into a customary separation and release agreement containing a general release of claims in favor of TWO.
  • · Madhur Agarwal, age 36, has served as CFO of CrossCountry Mortgage since 2021 and will continue in that role concurrently.
  • · Mr. Agarwal will not receive any compensation from TWO, and his CCM compensation will not be modified.
  • · Mr. Agarwal holds an MBA from Harvard Business School and a B.S. from the University of Pennsylvania.
  • · Mr. Agarwal has no material interests in transactions required to be disclosed under Item 404(a) of Regulation S-K.
GRAYBAR ELECTRIC CO INC 8-K neutral materiality 2/10

10-09-2026

Graybar Electric Co Inc announced the retirement of Senior Vice President - Human Resources, Beverly L. Propst, effective January 1, 2027. Propst, who joined Graybar in 2002, will retire after a 24-year career with the company. The filing contains no financial results or quantitative performance data.

  • · Propst joined Graybar in 2002 as Corporate Counsel, was promoted to Senior Corporate Counsel in 2003, named VP - Human Resources in 2008, and elected to the Board of Directors in 2009.
  • · Graybar is a Fortune 500 corporation and one of the largest employee-owned companies in North America.
  • · The company operates a network of 355 North American distribution facilities.
DEXCOM INC 8-K positive materiality 3/10

10-09-2026

Dexcom appointed Glenn Boehnlein, former CFO of Stryker Corporation, to its Board of Directors effective September 10, 2026. Boehnlein brings over 20 years of MedTech financial leadership to the board, which will support the company's long-range plan execution. No financial metrics were disclosed in this filing.

  • · Appointment effective September 10, 2026
  • · Boehnlein served as Stryker's VP and CFO from 2016 to 2025 and as advisor to Stryker's CEO from 2025 to 2026
  • · Boehnlein currently serves on boards of Inogen (Audit Committee Chair), Agilent Technologies, and Sutter Health
  • · He holds bachelor's and master's degrees in professional accountancy from Mississippi State University
New Fortress Energy Inc. 8-K neutral materiality 4/10

10-09-2026

On September 3, 2026, New Fortress Energy Inc. appointed Frederick Hundt, its Chief Accounting Officer, as interim Chief Financial Officer while the Board conducts a search for a permanent CFO. Mr. Hundt will serve as both principal financial and principal accounting officer. The filing does not disclose any financial metrics or period-over-period comparisons, so no performance data is available.

  • · Mr. Hundt joined NFE in June 2025 as Global Controller and became Chief Accounting Officer on July 1, 2026.
  • · Prior to NFE, he served as Corporate Controller at GXO Logistics from April 2023 to June 2025.
  • · He previously held finance leadership roles at Mastercard, including Assistant Corporate Controller, from 2015 to April 2023.
Matador Resources Co 8-K neutral materiality 4/10

10-09-2026

Matador Resources Company announced the retirement of Van H. Singleton, II as Co-President – Land, Acquisitions and Divestitures and Planning, effective September 9, 2026. Singleton will transition to a Special Advisor role to the Board and Executive Committee, with an annual fee of $450,000 paid monthly, while his outstanding equity awards will continue to vest. Bryan A. Erman will assume the Co-President role, and Jonathan J. Filbert will take over Singleton's land and M&A responsibilities.

  • · Singleton's role as Co-President assumed by Bryan A. Erman, who has served as Co-President, Chief Legal Officer and Head of M&A since June 2025.
  • · Jonathan J. Filbert, Executive Vice President – Land since October 2023, will assume Singleton's land and acquisition/divestiture responsibilities.
  • · The Advisor Agreement includes confidentiality, non-competition, and non-solicitation covenants.
  • · The term of the Advisor Agreement continues until terminated by either party.
Park Hotels & Resorts Inc. 8-K neutral materiality 5/10

10-09-2026

Park Hotels & Resorts Inc. granted one-time retention restricted stock awards (RSA) to four named executive officers on September 3, 2026, to mitigate leadership transition and recruiting risks. CEO Thomas J. Baltimore, Jr. received 331,564 shares, while other executives received smaller grants. The awards vest fully on the fourth anniversary, with accelerated vesting provisions for certain termination scenarios.

  • · The Retention RSA Awards vest in full on the fourth anniversary of the grant date, subject to continued employment.
  • · For executives other than Mr. Baltimore, termination without cause or due to retirement after the first anniversary results in full vesting; termination without cause within 12 months following a change in control also results in full vesting; death or disability triggers prorated vesting based on actual days employed during the vesting period.
  • · Mr. Baltimore's vesting upon termination is governed by his Executive Employment Agreement dated April 26, 2016.
  • · Award recipients will receive dividends on the restricted shares at the same time as regular dividend payments on common stock.
HERTZ GLOBAL HOLDINGS, INC 8-K neutral materiality 3/10

10-09-2026

On September 9, 2026, Hertz appointed Michael Moore as President of the Service Division and Chris Berg as President of the Rental Division, both effective immediately. These executive transitions are part of the Company's new Platform Operating Model, which aligns the enterprise around four business areas: Rental, Fleet, Service, and Oro Mobility. No financial figures or period-over-period comparisons are included in this filing.

  • · The new Platform Operating Model aligns the enterprise around four business areas: Rental, Fleet, Service, and Oro Mobility.
  • · Both appointments were effective as of September 9, 2026.
Reborn Coffee, Inc. 8-K neutral materiality 2/10

10-09-2026

Reborn Coffee, Inc. expanded its Board of Directors from seven to eight members and appointed James Lim and Edward Park to fill vacancies, effective September 3, 2026. The appointments bring the Board to eight directors, with both new members serving without compensation and not assigned to any committee. No related-party transactions or arrangements were disclosed.

  • · Board increased from 7 to 8 members on September 3, 2026.
  • · Prior to appointments, the Board had 6 directors; two vacancies were filled.
  • · Neither Mr. Lim nor Mr. Park will receive compensation for board service.
  • · Neither new director has been appointed to any board committee.
  • · No arrangements or understandings with other persons regarding their selection.
  • · No reportable related-party transactions under Item 404(a) of Regulation S-K.
NIKE, Inc. 8-K mixed materiality 6/10

10-09-2026

NIKE held its 2026 Annual Meeting on September 8, 2026, where shareholders approved all management proposals, including the election of directors, an advisory vote on executive compensation, ratification of PwC as auditor, and an increase in shares under the Employee Stock Purchase Plan. However, the advisory vote on executive compensation received significant opposition (349.5 million votes against, or about 32% of votes cast), and two shareholder proposals—one regarding charitable support discrimination and another on environmental targets—were overwhelmingly rejected. The company also disclosed the adoption of an amended Employee Stock Purchase Plan, increasing authorized shares by 16 million.

  • · All Class A directors were elected unanimously with 280,747,848 votes for each and zero votes withheld.
  • · Class B director Thasunda Duckett received 496,775,961 votes for and 310,517,784 withheld, indicating notable opposition.
  • · The advisory vote on executive compensation had 349,508,277 votes against (32% of votes cast), a significant level of dissent.
  • · Shareholder proposals on charitable support discrimination and environmental targets were rejected with only 0.7% and 10.3% support, respectively.
  • · The Employee Stock Purchase Plan amendment increases authorized shares by 16,000,000 and was approved with overwhelming support (1,081,095,618 for).
  • · Ratification of PwC as auditor passed with 1,175,590,556 votes for and 58,924,987 against.
Fortive Corp 8-K neutral materiality 3/10

10-09-2026

Fortive Corporation appointed Susan L. Main to its Board of Directors, effective September 9, 2026, increasing the board size from eight to nine members. Ms. Main will also serve on the Audit Committee and is deemed independent and an audit committee financial expert. She will receive standard non-employee director compensation as previously disclosed.

  • · Ms. Main's term expires at the 2027 Annual Meeting of Shareholders.
  • · She has entered into an indemnification agreement with the company.
  • · No arrangement or understanding exists between Ms. Main and any other person regarding her selection as director.
  • · No transactions requiring disclosure under Item 404(a) of Regulation S-K were identified.
CVD EQUIPMENT CORP 8-K negative materiality 9/10

10-09-2026

CVD Equipment Corporation announced a major restructuring plan, including discontinuing new system orders for its CVD equipment business and reducing its workforce by approximately half. The company expects a restructuring charge of $0.8M to $1.0M this quarter. Concurrently, President and CEO Emmanuel Lakios has left the company, and VP of Manufacturing Operations Warren Cheesman has been appointed Acting CEO. While the company has $23.5M in cash and no debt, the restructuring is driven by continued weakness in equipment orders, declining backlog, and ongoing operating losses in the CVD equipment division.

  • · The company will no longer pursue new system orders for its CVD equipment business, transitioning to a spare parts, quartz, and services business.
  • · The Board continues to evaluate opportunities to monetize assets, including its primary facility in Central Islip.
  • · Warren Cheesman has over 30 years of experience in engineering, operations, quality, and strategic sourcing across semiconductor, medical device, and defense equipment industries.
  • · The company had no debt as of the end of Q2 2026.
KADANT INC 8-K neutral materiality 6/10

10-09-2026

Kadant Inc. announced a CEO succession plan on September 10, 2026. Michael C. Colwell will become President and COO on October 1, 2026, and President, CEO, and a director on January 2, 2027, succeeding Jeffrey L. Powell, who will become Executive Chairman. Current Chairman Jonathan W. Painter will retire from the board on January 2, 2027. The plan ensures leadership continuity and retention of Mr. Powell for one year post-CEO transition.

  • · Mr. Colwell has been a senior vice president since December 2024 and previously led the Industrial Processing segment.
  • · Mr. Powell will serve as Executive Chairman for one year after stepping down as CEO, until his retirement on January 1, 2028.
  • · Mr. Painter has served as chairman for the last seven years and will retire from the board on January 2, 2027.
  • · The company has approximately 4,000 employees in 22 countries.
TransMedics Group, Inc. 8-K positive materiality 8/10

10-09-2026

TransMedics appointed Fernando Araujo as CFO effective September 21, 2026, succeeding Gerardo Hernandez who transitions to lead Latin American expansion. The company reiterated its full-year 2026 revenue guidance of $737M to $757M, representing 22%-25% YoY growth, while excluding any contribution from its recent investment in PAD Aviation Service GmbH.

  • · Fernando Araujo previously served as CFO of GE HealthCare's Advanced Imaging Solutions segment, a $16B business.
  • · Gerardo Hernandez will transition to Commercial Strategic Advisor, LATAM to lead TransMedics' expansion into Latin America.
  • · The 2026 revenue guidance excludes any contribution from the recent strategic investment in PAD Aviation Service GmbH.
  • · TransMedics management will present at Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, and Baird 2026 Global Healthcare Conference on September 15, 2026.
Ameresco, Inc. 8-K neutral materiality 4/10

10-09-2026

Ameresco, Inc. announced the designation of Julie Bradshaw as interim principal financial officer and Debbie Angelico as interim principal accounting officer, effective September 8, 2026, following the previously disclosed resignation of CFO Mark Chiplock (effective September 25, 2026). The company has commenced a search for a new CFO. Both appointees are internal Vice Presidents of Finance with no disclosed conflicts or family relationships.

  • · Julie Bradshaw joined Ameresco in April 2014 and has been VP Finance since January 2026; prior roles include Accounting Supervisor at Enterprise Holdings.
  • · Debbie Angelico joined Ameresco in August 2020 and has been VP Finance since January 2026; prior roles include Senior Manager of SEC Reporting at Covertus (1 year) and CFO of Next Level Now, Inc. (5 years).
  • · No arrangements or understandings exist regarding the appointments, and no family relationships or material interests in reportable transactions were disclosed.
Whitehawk Therapeutics, Inc. 8-K positive materiality 4/10

10-09-2026

Whitehawk Therapeutics appointed Vijay Iyengar, MD, to its Board of Directors, effective September 9, 2026. Dr. Iyengar brings over two decades of oncology experience, including nine years at Incyte where he helped grow annual revenue from approximately $1B to over $4B. The appointment is part of Whitehawk's growth phase as it advances its ADC portfolio, though the company remains a clinical-stage entity with inherent development risks.

  • · Dr. Iyengar previously held senior leadership roles in oncology at Novartis and was an Engagement Manager at McKinsey & Company.
  • · He holds a BS in Biology from Stanford University and an MD from Harvard Medical School.
  • · Whitehawk's ADC platform uses CPT113 as core linker-payload technology and its proprietary CBCR bioconjugation process.
  • · Whitehawk has an option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs.
  • · The company's ADC assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
FIVE STAR BANCORP 8-K neutral materiality 2/10

10-09-2026

On September 4, 2026, director Donna Lucas resigned from the Board of Directors of Five Star Bancorp effective immediately. The resignation was not due to any disagreement with the company. The Board expressed gratitude for her service.

  • · Resignation effective immediately as of September 4, 2026.
  • · No disagreement was cited as the reason for departure.
  • · The filing was signed by Heather Luck, EVP and CFO.
VITASPRING BIOMEDICAL CO. LTD. 8-K neutral materiality 6/10

10-09-2026

VitaSpring Biomedical Co., Ltd. announced a complete leadership change effective September 7, 2026. Dr. Ssu-Chuan Lai resigned as Chairperson, CEO, President, CFO, Secretary, and board member, with no disagreement cited. Jing-Zhou Chen was appointed CEO, President, CFO, and Secretary, and Shao-Hsiang Shih was elected as a director and Chairman. No compensatory arrangements were disclosed for either appointee.

  • · Dr. Lai's resignation was effective at 11:58 p.m. PT on September 7, 2026, immediately after her successor's election and appointment.
  • · Jing-Zhou Chen, age 40, previously founded and served as CEO of Dream Born Co., Ltd. (March 2025–present), and held roles at GBT Cloud Kitchen, Hongxi Enterprise Management, POKE25, G-Store Smart Retail Technology, Genes Tech, and STATS ChipPAC.
  • · Shao-Hsiang Shih, age 54, has been Director of Administrative Management at Century Publishing Co. since 2020, and holds a master's degree from Fo Guang University.
  • · No employment agreements or compensatory plans were entered into with Mr. Chen or Mr. Shih; compensation is subject to future Board determination.
  • · The Board has no standing committees (audit, compensation, nominating), and Mr. Shih has not been appointed to any committee.
SCYNEXIS INC 8-K neutral materiality 3/10

10-09-2026

SCYNEXIS announced the appointment of Sanjay Subramanian as CFO effective September 9, 2026, replacing Ivor Macleod who retired. Subramanian brings over 20 years of biopharma finance experience and was granted an option to purchase 100,000 shares at $4.91 as an inducement. The change is a routine leadership transition with no financial results or regulatory action involved.

  • · Subramanian previously served as CFO and Head of Business Development at Inozyme Pharma, leading its acquisition by BioMarin.
  • · He also served as CFO and Head of Corporate Development at Ocugen.
  • · The stock option vests over four years with one-fourth vesting on the one-year anniversary and the remainder monthly over 36 months.
  • · Macleod will remain with the company through October 9, 2026 to support transition.
  • · SCYNEXIS is a clinical-stage biotechnology company focused on severe rare diseases, with SCY-770 granted Orphan Drug designation for ADPKD.
HUNTINGTON BANCSHARES INC /MD/ 8-K neutral materiality 4/10

10-09-2026

Huntington Bancshares appointed Brantley J. Standridge as President, effective September 8, 2026, while Stephen D. Steinour remains Chairman and CEO. In connection with the appointment, Standridge's annualized base salary increased from $850,000 to $1,000,000, his annual incentive plan target rose from $1,487,500 to $1,850,000, and his long-term incentive plan target increased from $2,762,500 to $4,650,000. The filing does not include any financial results or period-over-period comparisons.

  • · Standridge, 50, previously served as Senior Executive Vice President and President of Consumer and Regional Banking since April 2023.
  • · Standridge joined Huntington from Truist Financial Corporation where he was Chief Retail Community Banking Officer after the BB&T/SunTrust merger.
  • · The compensation changes are effective September 15, 2026.
  • · The annual incentive plan target will be pro-rated for the time Standridge serves as President during 2026.
Candel Therapeutics, Inc. 8-K positive materiality 5/10

10-09-2026

Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors effective September 8, 2026, bringing over 30 years of global regulatory affairs and quality expertise as the company prepares for a planned Biologics License Application (BLA) submission for aglatimagene besadenovec in Q4 2026. The appointment strengthens the Board at a key inflection point toward potential commercial readiness, though the company remains a clinical-stage biopharmaceutical firm with no approved products and faces inherent regulatory and development risks.

  • · Dr. Zimmermann currently serves as EVP, Head of Regulatory Affairs, Quality and Alliance Management at Inventiva S.A., and previously held senior roles at Ipsen and Alexion Pharma International.
  • · Aglatimagene has Fast Track Designation and Regenerative Medicine Advanced Therapy Designation from the FDA for localized prostate cancer, Fast Track Designation in NSCLC, and both Fast Track and Orphan Drug Designation in PDAC.
  • · Linoserpaturev, the lead HSV platform candidate, is in an ongoing phase 1b trial in recurrent high-grade glioma with Fast Track and Orphan Drug Designations.
  • · The pivotal phase 3 trial for aglatimagene in localized prostate cancer was conducted under a Special Protocol Assessment with the FDA and published in The Lancet Oncology.
Versus Systems Inc. 8-K neutral materiality 3/10

10-09-2026

Versus Systems Inc. appointed Brian Goldenberg as CFO, Principal Financial Officer, and Principal Accounting Officer, effective September 8, 2026. CEO Luis Goldner will step down from the Principal Financial Officer role. The filing contains no financial results or performance data.

  • · Brian Goldenberg served as COO, CCO, and CFO of Divisadero Street Capital Management from Nov 2023 to Feb 2026.
  • · Prior to that, he was CFO of Trend Capital Management from Feb 2018 to Nov 2023.
  • · The company is an emerging growth company and has elected not to use the extended transition period for complying with new financial accounting standards.
Ramaco Resources, Inc. 8-K neutral materiality 3/10

10-09-2026

Former U.S. Senator Joe Manchin is stepping down from the Board of Directors of Ramaco Resources, Inc. to focus on his independent leadership council movement. The company expressed deep appreciation for his service and stated it fully respects his decision, while Manchin affirmed he remains a strong supporter of Ramaco.

  • · Ramaco Resources operates four active metallurgical coal mining complexes in Central Appalachia and one exploration-stage coal and rare earth property (Brook Mine) in Wyoming.
  • · The company also operates a carbon research facility contiguous to the Brook Mine and holds over 70 intellectual property patents, pending applications, exclusive licensing agreements, and trademarks.
  • · Manchin's departure is effective immediately upon the announcement, with no specific successor named.
QUAINT OAK BANCORP, INC. 8-K neutral materiality 2/10

10-09-2026

Quaint Oak Bancorp, Inc. appointed Mr. Ray S. Greenberg, CFP, as a director of the Company effective September 9, 2026, with his initial term expiring at the 2029 annual meeting. Mr. Greenberg has served on the board of the Company's wholly owned subsidiary, Quaint Oak Bank, since 2016 and was also appointed to the Company's Audit Committee. The filing contains no financial results, no period-over-period comparisons, and no material quantitative data.

  • · Mr. Greenberg previously served as an Advisory Board Member of the Company from May 2017 to September 2026.
  • · He is the owner of Financial Expertise, a sole proprietorship based in Feasterville, Pennsylvania.
  • · He has held the Certified Financial Planner designation since 1990.
  • · He serves as Chair of the Bank Board's Directors' Compliance Oversight Committee, Loan Committee, and Pandemic Committee.
  • · There are no arrangements or understandings with any other person regarding his selection as director.
  • · No family relationships with any director or executive officer requiring disclosure.
  • · No transactions requiring disclosure under Item 404(a) of Regulation S-K.
Summit Networks Inc. 8-K negative materiality 6/10

10-09-2026

Summit Networks Inc. disclosed that Independent Director and Audit Committee Chairman Ross Miller submitted two conflicting resignation letters on August 31, 2026 and September 8, 2026, citing a breakdown in communication and differences over the company's future direction. The Board has not yet taken any action or expressed a position on either letter. The uncertainty surrounding the director's resignation and the lack of board response raise governance concerns.

  • · The first resignation letter (August 31, 2026) stated resignation effective January 1, 2027.
  • · The second resignation letter (September 8, 2026) stated resignation effective September 8, 2027.
  • · Both letters referenced a breakdown in communication and differences regarding the Company’s future direction and business plans.
  • · As of the filing date (September 10, 2026), the Board had not taken any action or expressed any position with respect to either resignation letter.
Golden Minerals Co 8-K neutral materiality 5/10

10-09-2026

Golden Minerals Company announced the resignation of President and CEO Pablo Castanos, effective September 30, 2026, and the appointment of director David Watkins as his successor. Additionally, the company noted that its partner Cascadero Copper Corporation has agreed to sell its interests in the Sarita Este and Desierto projects in Argentina to Lumina Copper Corporation, an affiliate of First Quantum Minerals. Golden Minerals is planning a first-stage drill program at the Desierto concessions and expects to announce details later in September.

  • · Pablo Castanos will continue to serve as a director after his resignation as President and CEO.
  • · David Watkins has been a director of the company since 2009 and is an exploration geologist and seasoned mining executive.
  • · The drill program targets potentially deep mineralization similar to First Quantum's Taca Taca project, which is immediately north of Golden's Desierto concessions.
  • · The sale of Cascadero's interests to Lumina Copper is subject to completion; Golden looks forward to working with First Quantum if the sale closes.
Stark Focus Group, Inc. 8-K neutral materiality 3/10

10-09-2026

Stark Focus Group, Inc. filed an 8-K on September 10, 2026, disclosing officer changes (Item 5.02), amendments to articles/bylaws (Item 5.03), and exhibits (Item 9.01). The filing does not specify the officer position, whether it is an appointment or resignation, or the reason for the change. No financial metrics, compensation details, or forward-looking guidance were disclosed.

  • · Filing size: 916 KB, suggesting detailed exhibits may be included.
  • · AccNo: 0001640334-26-001489, filed on 2026-09-10.
  • · Sector not specified in the filing.
APTARGROUP, INC. 8-K neutral materiality 3/10

10-09-2026

AptarGroup, Inc. announced the resignation of Aditya J. Gandhi as Vice President, Chief Accounting Officer, effective September 11, 2026, to pursue an opportunity outside the Chicago area. The Board appointed Daniel Ackerman as Senior Vice President, Interim Chief Accounting Officer, effective the same date, resuming a role he previously held until June 2026. Mr. Ackerman will serve as principal accounting officer and report to the CFO.

  • · Mr. Gandhi's resignation was not due to any disagreement with the company regarding operations, policies, or practices.
  • · Daniel Ackerman previously served as Chief Accounting Officer from August 1, 2024 to June 8, 2026.
  • · Mr. Ackerman joined AptarGroup in 2015 as Vice President, Corporate Controller.
  • · No arrangements or understandings exist between Mr. Ackerman and any other persons regarding his appointment.
  • · No family relationships between Mr. Ackerman and any director or executive officer, and no disclosable transactions under Item 404(a).
Beauty Health Co 8-K neutral materiality 3/10

10-09-2026

Beauty Health Co (SKIN) promoted CFO Michael Monahan to Chief Financial and Operating Officer, effective September 3, 2026. His expanded role now includes oversight of supply chain, manufacturing, logistics, and customer experience in addition to financial operations. His base salary will increase from $515,000 to $555,000 effective September 15, 2026.

  • · No family relationships exist between Mr. Monahan and any director or other executive officer.
  • · No transactions between Mr. Monahan and the company requiring disclosure under Item 404(a) of Regulation S-K.
  • · Mr. Monahan's biographical information is available in the company's definitive proxy statement filed April 24, 2026.

Get daily alerts with 9 investment signals, 9 risk alerts, 6 opportunities and full AI analysis of all 37 filings

$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.

More from: US Corporate Board Director Changes SEC Filings

🇺🇸 More from United States

View all →